financetom
Business
financetom
/
Business
/
PLTR Stock, Up Over 80% In The Past Two Months, Trades Nearly 5% Lower In Friday Premarket After UBS Says 'Valuation…Is Simply Tough To Get Over'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PLTR Stock, Up Over 80% In The Past Two Months, Trades Nearly 5% Lower In Friday Premarket After UBS Says 'Valuation…Is Simply Tough To Get Over'
Dec 20, 2024 5:59 AM

Palantir Technologies Inc ( PLTR ) , which has seen a notable rise in its stock price over the past two months, is now facing a downturn in Friday pre-market trading.

What HappenedPalantir Technologies Inc ( PLTR ) saw a significant rise of over 78% in the last two months. However, data from Benzinga Pro showed that on Friday the stock fell by 3.62% during pre-market trading.

This decline follows the initiation of coverage by UBS analyst Karl Kierstead, who gave Palantir ( PLTR ) a neutral rating on Dec. 18. Kierstead expressed optimism about Palantir’s fundamentals but highlighted concerns over its valuation. “Our review of Palantir’s fundamentals left us very positive. In our view, Palantir ( PLTR ) deserves a material multiple premium to most/all other public software firms,” he said, reported Investor’s Business Daily.

“The main thing keeping us on the sidelines is valuation, which at 49 times revenue and 124 times free cash flow on 2025 estimates is simply tough to get over.”

Why It Matters: Palantir ( PLTR ) has a consensus price target of $34.13 based on the ratings of 21 analysts, tracked by Benzinga Pro. The three most recent analyst ratings were released by Benchmark, UBS, and Mizuho set an average price target of $44 with an implied 39.04% downside for Palantir ( PLTR ).

Palantir ( PLTR ) on Thursday announced an extension of its partnership with the U.S. Army, which is expected to enhance its data and AI capabilities. The agreement, valued at $400.7 million over four years, has a potential ceiling of $618.9 million. This partnership aims to operationalize data across the Department of the Army, enabling broader integration of data and AI capabilities.

Read Next: 

Trump Inauguration Could Coincide With A ‘Harrowing Dump’ For Crypto, Arthur Hayes Warns

Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Image via Flickr

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lightspeed Commerce Shares Rise After Better-Than-Expected Fiscal Q2 Earnings
Lightspeed Commerce Shares Rise After Better-Than-Expected Fiscal Q2 Earnings
Nov 6, 2025
10:05 AM EST, 11/06/2025 (MT Newswires) -- Lightspeed Commerce ( LSPD ) shares were up over 9% in recent Thursday trading after the company posted fiscal Q2 numbers that exceeded analyst estimates. The company reported fiscal Q2 adjusted earnings of $0.16 per diluted share, up from $0.13 a year earlier. Analysts polled by FactSet expected $0.12. Revenue for the quarter...
Canada Goose Shares Tumble Following Fiscal Q2 Loss
Canada Goose Shares Tumble Following Fiscal Q2 Loss
Nov 6, 2025
10:07 AM EST, 11/06/2025 (MT Newswires) -- Canada Goose (GOOS) shares were down more than 14% in recent trading Thursday after the company reported that it swung to fiscal Q2 adjusted loss. The company reported a fiscal Q2 adjusted net loss of 0.14 Canadian dollar ($0.10) per diluted share, swinging from adjusted earnings of CA$0.05 a year earlier. Analysts surveyed...
AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable
AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable
Nov 6, 2025
AstraZeneca Plc ( AZN ) on Thursday reported third-quarter 2025 sales of $15.19 billion, up 12% year over year (+10% at constant currency), beating the consensus of $14.80 billion, driven by double-digit growth in oncology, CVRM, and biopharmaceuticals. The company’s adjusted EPADS reached $1.19, beating the consensus of $1.14. The adjusted EPS was $2.38 (1 ADR = 2 Common Shares)....
Form 8.3
Form 8.3
Nov 6, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Copyright 2023-2026 - www.financetom.com All Rights Reserved